In 2024, Biopôle-based companies achieved remarkable milestones, solidifying the campus’s position as a leading hub for life sciences innovation. With over CHF 246 million raised in funding, major commercial agreements, groundbreaking clinical trials, and international recognition, Biopôle continues to foster a thriving ecosystem for growth and collaboration.
Top fundraising rounds
In 2024, Biopôle companies raised over CHF 246 million, a testament to the campus’s position as a leading hub for innovation and growth in life sciences. Here are the top 5 fundraising achievements:
- ADC Therapeutics: $105M offering for cancer therapy advancements.
- Arga Medtech: €54M oversubscribed Series B funding.
- Vandria: $30.7M Series A for mitophagy therapies.
- Orbis Medicines: €26M seed financing for biopharmaceutical developments.
- Volumina Medical: $21M to continue clinical programs for regenerative medicine.
Grants
In 2024, several Biopôle-based companies secured prestigious grants and funding, driving advancements across diverse areas of life sciences and health technology, here a selection:
- Cellestia Biotech selected for a CHF 2m grant from Innosuisse.
- Novigenix-led project received €1.75m grant to improve patient outcomes using liquid biopsy technology.
- PeriVision, Inselspital and the University of Bern receive CHF 1.1m grant to develop new fixation-independent perimetry for retinal diseases.
- Limula obtained CHF 500’000 by FIT Tech Growth loan, after an initial Tech Grant and a Tech Seed loan awarded by FIT in 2019 and 2022.
- Nexco Analytic was awarded a FIT Tech Seed loan of CHF 100,000.
- Neuria received CHF 150,000 by Venture Kick to address overweight treatment with neuroscience-powered digital health solution.
Commercial agreements
This year, Haya Therapeutics impressed the start-up ecosystem by announcing a $ 1 billion commercial deal with global leader Eli Lilly, a transformative partnership focusing on obesity and metabolic conditions. Such commercial agreements demonstrate the growing strength of Biopôle-based companies in forging impactful collaborations. Biopôle companies engaged in numerous strategic alliances in 2024, here is a selection:
- AKYmed partnered with Rara Avis Biotec to revolutionize animal reproduction solutions.
- Aspivix and Bayer Schweiz to transform gynecological procedures.
- Atinary announced a major partnership with Takeda and Snapdragon Chemistry, a Cambrex company.
- Impli and Bayer to advance Impli’s hormone monitoring device
- PeriVision signed a clinical trial agreement with Genentech, Roche’s US business unit.
